HUB Investment Partners LLC Cuts Holdings in United Therapeutics Co. (NASDAQ:UTHR)

HUB Investment Partners LLC trimmed its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 19.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 695 shares of the biotechnology company’s stock after selling 165 shares during the quarter. HUB Investment Partners LLC’s holdings in United Therapeutics were worth $245,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of UTHR. Wealthfront Advisers LLC increased its holdings in United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the period. World Investment Advisors LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $139,206,000. FMR LLC increased its holdings in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock valued at $386,168,000 after buying an additional 314,004 shares during the period. Thrivent Financial for Lutherans increased its holdings in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after buying an additional 189,967 shares during the period. Finally, AustralianSuper Pty Ltd increased its holdings in United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after buying an additional 161,751 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 90,255 shares of company stock worth $32,614,521 over the last three months. Company insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 0.2 %

NASDAQ:UTHR opened at $312.99 on Friday. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The firm has a fifty day simple moving average of $345.10 and a 200-day simple moving average of $357.02. The company has a market capitalization of $14.06 billion, a P/E ratio of 13.75, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the previous year, the firm posted $4.36 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.